Publication | Closed Access
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
43
Citations
13
References
2015
Year
On the basis of the commonly accepted willingness-to-pay threshold ($20,301.00/QALY in China), sorafenib is not a cost-effective option as a first-line treatment for patients with advanced HCC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1